Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1973 2
1980 1
1983 1
1985 2
1986 1
1987 1
1988 2
1989 2
1991 1
1992 2
1993 1
2005 1
2013 1
2014 1
2019 1
2020 3
2021 3
2022 4
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

33 results

Results by year

Filters applied: . Clear all
Page 1
[Levilimab and baricitinib prescribing experience in outpatient COVID-19 patients' treatment].
Khripun AI, Starshinin AV, Antipova YO, Lysenko MA, Urozhaeva YV, Gavrilenko OF, Rusantsova NA, Tyazhelnikov AA, Tikhonovskaya EY, Okolot NV, Sokolova MV, Fomina DS, Simonova EN, Kruglova TS, Chernov AA, Zagrebneva AI. Khripun AI, et al. Among authors: kruglova ts. Ter Arkh. 2022 Jun 17;94(5):668-674. doi: 10.26442/00403660.2022.05.201676. Ter Arkh. 2022. PMID: 36286967 Russian.
Real-world clinical effectiveness of Tixagevimab/Cilgavimab and Regdanvimab monoclonal antibodies for COVID-19 treatment in Omicron variant-dominant period.
Fomina DS, Lebedkina MS, Iliukhina AA, Kovyrshina AV, Shelkov AY, Andreev SS, Chernov AA, Dolzhikova IV, Kruglova TS, Andrenova GV, Tukhvatulin AI, Shcheblyakov DV, Karaulov AV, Lysenko MA, Logunov DY, Gintsburg AL. Fomina DS, et al. Among authors: kruglova ts. Front Immunol. 2023 Oct 20;14:1259725. doi: 10.3389/fimmu.2023.1259725. eCollection 2023. Front Immunol. 2023. PMID: 37928549 Free PMC article. Clinical Trial.
[Pre-exposure prophylaxis of new COVID-19 coronavirus infection with tixagevimab/cilgavimab in adult Moscow patients with primary immunodeficiencies].
Roppelt AA, Lebedkina MS, Chernov AA, Kruglova TS, Mukhina OA, Yukhnovskaya YD, Samedova FA, Mаrkina UA, Andrenova GV, Karaulov AV, Lysenko MA, Fomina DS. Roppelt AA, et al. Among authors: kruglova ts. Ter Arkh. 2023 Feb 24;95(1):78-84. doi: 10.26442/00403660.2023.01.202088. Ter Arkh. 2023. PMID: 37167118 Russian.
[Efficacy and safety of regdanvimab in patients with mild/moderate COVID-19 and high risk of progression of the disease: a retrospective study in a short-term stay unit].
Markina UA, Fomina DS, Lebedkina MS, Kruglova TS, Chernov AA, Zagrebneva AI, Mutovina ZY, Karaulov AV, Alexeeva EI, Lysenko MA. Markina UA, et al. Among authors: kruglova ts. Ter Arkh. 2022 Jun 17;94(5):675-682. doi: 10.26442/00403660.2022.05.201690. Ter Arkh. 2022. PMID: 36286968 Russian.
33 results